neffy® epinephrine nasal spray receives Health Canada approval
Article Source: https://foodallergycanada.ca/neffy-epinephrine-nasal-spray-receives-health-canada-approval
Today, ALK Canada announced that neffy® epinephrine nasal spray has been approved by Health Canada. The approval is for a 2 mg dose for treating anaphylaxis in adults and children weighing 30 kg (66 lbs) or greater.
ALK has advised that neffy will be widely available in pharmacies across Canada starting in summer 2026. With neffy, Canadians will have access to a different option for an epinephrine device.
ALK’s statement
Read ALK’s statement for details on the neffy launch and other product details.
FAQs
The FAQs address questions you may have about neffy.
We have advocated on your behalf for greater access to epinephrine.
The approval of neffy marks an important step forward — giving Canadians another option and the ability to choose the device that best meets their needs.
Our advocacy has focused on ensuring there are a minimum of two affordable epinephrine device options available in Canada, helping to reduce the risks associated with a single-source market, including supply shortages and limited flexibility.
We’ve worked closely with the Government of Canada, provincial governments, pharmaceutical companies, and other key stakeholders to help make this progress possible — always with the goal of improving access and choice for the community.
As new epinephrine device options continue to emerge, we remain committed to advocating strongly and consistently to ensure Canadians can access the full range of options.
For additional details about the launch, please visit neffy.ca or contact ALK directly at ca-info@alk.net.